Hilton Head Capital Partners »

Galectin Therapeutics shares owned by Hilton Head Capital Partners

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by Hilton Head Capital Partners from 13F filings

Historical chart of Hilton Head Capital Partners investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by Hilton Head Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by Hilton Head Capital Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.2k 800 2.79

More positions owned by Hilton Head Capital Partners

First Trust Etf Iv First Trust Enhanced Short First Tr Enh New (FTSM)
Ft Vest S&p 500 Dividend Aristocrats Target Income Etf Ft Vest S&p 500 (KNG)
Ft Vest Laddered Buffer Etf Ft Vest Laddered (BUFR)
Schwab Us Dividend Equity Etf Us Dividend Eq (SCHD)
Eli Lilly & Co. (LLY)
Amazon (AMZN)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
First Trust Capital Strength Etf Cap Strength Etf (FTCS)
Philip Morris International (PM)
Wal-Mart Stores (WMT)
First Trust Nasdaq Rising Dividend Achievers Risng Divd Achiv (RDVY)
Johnson & Johnson (JNJ)
Lam Research Corporation Com New (LRCX)

View all positions for Hilton Head Capital Partners

Top funds holding Galectin Therapeutics

Vanguard Group
Vanguard Capital Management
Advisor Group Holdings
Susquehanna International
Dr. Jeffrey R. Jay, M.D.
BlackRock
Millennium Management
Sontag Advisory
Geode Capital Management
Marshall Wace
Two Sigma Investments
Commonwealth Equity Services
Citadel Advisors
Jane Street
Vanguard Fiduciary Trust

View all funds holding Galectin Therapeutics